BlackRock Institutional Trust’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

BlackRock Institutional Trust’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$48.1M	Buy	442,854 +5,517	+1%	+$657K	0.01%	1376
2016 Q3	$72M	Buy	437,337 +21,523	+5%	+$3.39M	0.01%	1070
2016 Q2	$59.3M	Buy	415,814 +3,813	+0.9%	+$556K	0.01%	1134
2016 Q1	$52.9M	Sell	412,001 -3,375	-0.8%	-$399K	0.01%	1185
2015 Q4	$62M	Buy	415,376 +8,379	+2%	+$1.42M	0.01%	1121
2015 Q3	$67.5M	Buy	406,997 +60,949	+18%	+$13.4M	0.01%	1056
2015 Q2	$83.5M	Buy	346,048 +17,192	+5%	+$4.58M	0.01%	1001
2015 Q1	$92.7M	Buy	328,856 +9,915	+3%	+$2.15M	0.01%	972
2014 Q4	$49.8M	Buy	318,941 +11,047	+4%	+$2.04M	0.01%	1301
2014 Q3	$72.9M	Buy	307,894 +8,530	+3%	+$2.17M	0.01%	1028
2014 Q2	$70.8M	Buy	299,364 +64,633	+28%	+$17M	0.01%	1093
2014 Q1	$77.4M	Buy	234,731 +153,164	+188%	+$51.7M	0.01%	1024
2013 Q4	$5.57M	Sell	81,567 -2,161	-3%	-$125K	﹤0.01%	2726
2013 Q3	$5.78M	Buy	83,728 +13,349	+19%	+$659K	﹤0.01%	2657
2013 Q2	$3.16M	Buy	+70,379	New	+$2.4M	﹤0.01%	2891

Other funds holding ICPT

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Carmignac Gestion Paris, France $7.71B AUM 4.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

BlackRock Institutional Trust's ICPT Position: Q4 2016 in Review

BlackRock Institutional Trust increased its Intercept Pharmaceuticals, Inc. (ICPT) stake by 1.3% in Q4 2016, buying an estimated $657K and bringing the position to 442,854 shares worth $48.1M. The position accounts for 0.01% of the portfolio, ranked #1376.

BlackRock Institutional Trust first reported a position in ICPT in Q2 2013 and has held it in 15 quarters since. The position peaked at $92.7M in Q1 2015. 159 funds tracked by Wall St. Rank hold ICPT as of Q4 2016.

BlackRock Institutional Trust held 442,854 shares of Intercept Pharmaceuticals, Inc. worth $48.1M as of Q4 2016.
BlackRock Institutional Trust bought 5,517 Intercept Pharmaceuticals, Inc. shares in Q4 2016, an estimated $657K.
Intercept Pharmaceuticals, Inc. made up 0.01% of BlackRock Institutional Trust's portfolio in Q4 2016, its #1376 holding.
BlackRock Institutional Trust first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2013 and has held it in 15 quarters since.
BlackRock Institutional Trust's Intercept Pharmaceuticals, Inc. position peaked at $92.7M in Q1 2015.
159 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2016.

Based on BlackRock Institutional Trust's 13F filing for Q4 2016, filed 10 Feb 2017.